Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

RECRUITING

Identifier: CI-TRIAL-00060382
Entity page: /trial/NCT05503667 ↗
Edges: 4

Neighbours: 1 cancers2 drugs
Drawn: 3 of 3 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma condition of …CONDITION_OFderived2 of 2
← condition of	Lung Adenocarcinoma registry condition “Lung Adenocarcinoma Stage III” mapped CURATED_BROADER	—	—	Lung Adenocarcinoma	1	Observed	clinicaltrials	graph →
← condition of	Lung Adenocarcinoma registry condition “Lung Adenocarcinoma Stage IV” mapped CURATED_BROADER

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma intervention of …INTERVENTION_OFderived2 of 2
← intervention of	Bevacizumabmonoclonal antibody registry intervention “Bevacizumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Firmonertinibsmall molecule registry intervention “Furmonertinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma intervention of …INTERVENTION_OFderived2 of 2

← intervention of

Bevacizumabmonoclonal antibody

registry intervention “Bevacizumab” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →